The Vanguard Group, Inc. has recently announced that it has increased stake in OncoCyte Corporation (NASDAQ:OCX) by 0.06%. After grabbing 4.31 million shares, the institutional investor is now in possession of 2500.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 3.64% having worth around $1.57 million.
OncoCyte Corporation (OCX) concluded trading on 03/16/23 at a closing price of $0.30, with 7.12 million shares of worth about $2.14 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -66.70% during that period and on Thursday the price saw a gain of about 51.50%. Currently the company’s common shares owned by public are about 118.61M shares, out of which, 106.54M shares are available for trading.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $1.40 and could fall to a lowest price of $0.40. However, touching the estimated high of $1.40 would mean a gain of 78.57% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 64 times over the past 12 months. They bought 20,162,963 shares in 57 of the transactions. In 7 selling transactions, insiders dumped 432,514 shares.
Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in OncoCyte Corporation Vanguard Total Stock Market Index is currently holding 3.08 million shares of worth totaling $1.12 million. The company recently came buying 0.0 shares which brought its stake up to 2.60% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 0.6 million shares, have now control over 0.51% of the stake in the company. It holds 0.0 shares of worth $0.22 million.
OncoCyte Corporation (NASDAQ: OCX) started trading at $0.21, above $0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 0.3580, or with a gain of 51.50%. Stock saw a price change of -18.11% in past 5 days and over the past one month there was a price change of -29.53%. Year-to-date (YTD), OCX shares are showing a performance of -5.58% which decreased to -73.65% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.20 but also hit the highest price of $1.68 during that period. The average intraday trading volume for OncoCyte Corporation shares is 359.19K. The stock is currently trading -15.77% below its 20-day simple moving average (SMA20), while that difference is down -23.02% for SMA50 and it goes to -54.69% lower than SMA200.
The Vanguard Group, Inc. acquired 4.31 million shares of OncoCyte Corporation having value of about $1.57 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 2500.0 shares in the company valued at close to $750.0, or have control over 0.06% stake in the company. OncoCyte Corporation (NASDAQ: OCX) currently have 118.61M outstanding shares and institutions hold larger chunk of about 59.70% of that. Holding of mutual funds in the company is about 5.02% while other institutional holders and individual stake holders have control over 57.22% and 43.26% of the stake respectively.
The stock has a current market capitalization of $38.78M and its 3Y-monthly beta is at 1.63. It has posted earnings per share of -$0.66 in the same period. It has Quick Ratio of 2.80 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OCX, volatility over the week remained 35.28% while standing at 16.53% over the month.
Stock’s fiscal year EPS is expected to drop by -57.70% while it is estimated to increase by 11.10% in next year.
Analysts at 5 brokerage firms have issued recommendations for the OncoCyte Corporation (OCX)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.60. Out of those 5 Wall Street analysts, 2 recommended a “Buy” rating, while 3 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
On January 07, 2022, Stephens Initiated their recommendations, while on January 06, 2022, Piper Sandler Resumed their ratings for the stock with a price target of $3.10. Stock get a Buy rating from Needham on March 17, 2021.
